natgillin/translations-raw huggingface dataset:
In most of these cases patients have had a prior history of pancreatitis and/ or concurrent therapy with other medicinal products associated with pancreatitis.
Večinoma so imeli ti bolniki anamnezo pankreatitisa in/ ali hkratnega zdravljenja z drugimi zdravili, povezanimi s pankreatitisom.
In some of these the hyperglycaemia was severe and in some cases also associated with ketoacidosis.
Bolnike s temi znaki oz. simptomi je treba pregledati.
Many patients had confounding medical conditions some of which required therapy with agents that have been associated with the development of diabetes mellitus or hyperglycaemia.
Če se diagnoza pankreatitisa potrdi, je treba zdravljenje z zdravilom Kaletra prekiniti (glejte poglavje 4. 8).
4 Fat redistribution & metabolic disorders
4 Hiperglikemija
Combination antiretroviral therapy has been associated with redistribution of body fat (lipodystrophy) in HIV patients.
Kombinirano protiretrovirusno zdravljenje je bilo pri bolnikih s HIV povezano s prerazporeditvijo telesnega maščevja (lipodistrofijo).
The long-term consequences of these events are currently unknown.
Dolgotrajne posledice tega trenutno niso znane.
A connection between visceral lipomatosis and protease inhibitors (PIs) and lipoatrophy and nucleoside reverse transcriptase inhibitors (NRTIs) has been hypothesised.
Domnevajo, da obstaja povezava med visceralno lipomatozo in zaviralci proteaz (ZP) ter lipoatrofijo in nukleozidnimi zaviralci reverzne transkriptaze.
A higher risk of lipodystrophy has been associated with individual factors such as older age, and with drug related factors such as longer duration of antiretroviral treatment and associated metabolic disturbances.
Večje tveganje za lipodistrofijo je povezano z individualnimi dejavniki, npr. večjo starostjo, in dejavniki, povezanimi z zdravili, npr. z dolgotrajnejšim protiretrovirusnim zdravljenjem in spremljajočimi presnovnimi motnjami.
Consideration should be given to measurement of fasting serum lipids and blood glucose.
Razmisliti je treba o merjenju koncentracije lipidov v serumu in glukoze v krvi na tešče.
Lipid disorders should be managed as clinically appropriate (see section 4.8).
Motnje lipidov je treba obravnavati, kot je klinično ustrezno (glejte poglavje 4. 8).
Lopinavir/ ritonavir has been shown to cause modest asymptomatic prolongation of the PR interval in some healthy adult subjects.
Ugotovljeno je, da kombinacija lopinavir/ ritonavir nekaterim zdravim odraslim osebam zmerno in asimptomatsko podaljša interval PR.
Rare reports of 2nd or 3rd degree atroventricular block in patients with underlying structural heart disease and pre-existing conduction system abnormalities or in patients receiving drugs known to prolong the PR interval (such as verapamil or atazanavir) have been reported in patients receiving lopinavir/ ritonavir.
Med zdravljenjem z lopinavirjem/ ritonavirjem so redko poročali o atrioventrikularnem bloku 2. ali 3. stopnje pri bolnikih, ki so imeli osnovno organsko bolezen in že obstoječe nepravilnosti prevodnega sistema, in bolnikih, zdravljenih z zdravili, ki podaljšajo interval PR (npr. verapamil ali atazanavir).
Kaletra should be used with caution in such patients (see section 5.1).
Zdravilo Kaletra morate pri takšnih bolnikih uporabljati previdno (glejte poglavje 5. 1).
These increases of plasma concentrations of co-administered medicinal products could increase or prolong their therapeutic effect and adverse events (see sections 4.3 and 4.5).
Zvečana koncentracija sočasno uporabljenih zdravil v plazmi lahko zveča ali podaljša njihov terapevtski učinek in neželene učinke (glejte poglavji 4. 3 in 4. 5).
The HMG-CoA reductase inhibitors simvastatin and lovastatin are highly dependent on CYP3A for metabolism, thus concomitant use of Kaletra with simvastatin or lovastatin is not recommended due to an increased risk of myopathy including rhabdomyolysis.
Previdnost je potrebna tudi pri hkratni uporabi
Caution must also be exercised and reduced doses should be considered if Kaletra is used concurrently with rosuvastatin or with atorvastatin, which is metabolised to a lesser extent by CYP3A4.
5 zdravila Kaletra z rosuvastatinom ali z atorvastatinom, ki se v manjši meri presnavlja s CYP3A4; razmisliti je treba o zmanjšanju odmerkov.
If treatment with a HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended (see section 4.5).
Če je indicirano zdravljenje z zaviralcem reduktaze HMG - CoA, sta priporočljiva pravastatin ali fluvastatin (glejte poglavje 4. 5).
Indeed, Kaletra could increase concentrations of the co-administered medicinal products and this may result in
Zdravilo Kaletra lahko dejansko zveča koncentracijo hkrati uporabljenih zdravil, to pa lahko zveča njihove neželene kardialne učinke.
Cardiac events have been reported with Kaletra in preclinical studies; therefore, the potential cardiac effects of Kaletra cannot be currently ruled out (see sections 4.8 and 5.3).
V predkliničnih raziskavah z zdravilom Kaletra so poročali o kardialnih incidentih, zato možnih učinkov zdravila Kaletra na srce trenutno ni mogoče izključiti (glejte poglavji 4. 8 in 5. 3).
Rifampicin in combination with Kaletra causes large decreases in lopinavir concentrations which may in turn significantly decrease the lopinavir therapeutic effect.
Rifampicin v kombinaciji z zdravilom Kaletra povzroči veliko zmanjšanje koncentracij lopinavirja s posledičnim pomembnim zmanjšanjem terapevtskega učinka lopinavirja.
Adequate exposure to lopinavir/ ritonavir may be achieved when a higher dose of Kaletra is used but this is associated with a higher risk of liver and gastrointestinal toxicity.
Zadostno izpostavljenost kombinaciji lopinavir/ ritonavir se lahko doseže z uporabo višjega odmerka zdravila Kaletra, vendar je to povezano z večjim tveganjem za jetrno in gastrointestinalno toksičnost.
Therefore, this co-administration should be avoided unless judged strictly necessary (see section 4.5).
Zato naj se taka sočasna uporaba izogiba, razen če se presodi, da je absolutno potrebna (glejte poglavje 4. 5).
Kaletra is not recommended for use in children less than 2 years of age because of limited efficacy and safety data.
Zaradi omejenih podatkov o učinkovitosti in varnosti zdravila Kaletra ni priporočljivo uporabljati pri otrocih, mlajših od 2 let.
It does not reduce the risk of passing HIV to others through sexual contact or contamination with blood.
Prav tako ne zmanjša tveganja za prenos HIV na druge s spolnim stikom ali s kontaminacijo s krvjo.
Appropriate precautions should be taken.
Upoštevati je treba ustrezne previdnostne ukrepe.
There are limited data on salvage therapy on patients who have failed with Kaletra.
Podatki o rešilnem zdravljenju pri bolnikih, pri katerih zdravilo Kaletra ni bilo uspešno, so omejeni.
There are ongoing studies to further establish the usefulness of potential salvage therapy regimens (e. g. amprenavir or saquinavir).
Trenutno potekajo raziskave za dodatno ugotavljanje uporabnosti možnih rešilnih terapevtskih shem (npr. amprenavirja ali sakvinavirja).
There are currently limited data on the use of Kaletra in protease inhibitor-experienced patients.
Podatki o uporabi zdravila Kaletra pri bolnikih, izkušenih z zaviralci proteaz, so trenutno omejeni.
Kaletra soft capsules contain sunset yellow [E110] as an excipient, which can cause allergic-type reaction.
Mehke kapsule Kaletra kot pomožno snov vsebujejo oranžno barvilo FCF [E110], ki lahko povzroči alergijsko reakcijo.
Allergy is more common in those people who are allergic to aspirin.
Alergija je pogostejša pri ljudeh, alergičnih na acetilsalicilno kislino (Aspirin).
Concomitant use of Kaletra and fluticasone or other glucocorticoids that are metabolised by CYP3A4 is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects, including Cushing’ s syndrome and adrenal suppression (see section 4.5).
Sočasne uporabe zdravila Kaletra in flutikazona ali drugih glukokortikoidov, ki se presnavljajo s CYP3A4, ne priporočamo, razen v primerih, ko možne koristi zdravljenja prevladajo nad tveganjem za pojav sistemskih kortikosteroidnih učinkov, vključno s Cushingovim sindromom in z zaviralnim vplivom na nadledvično žlezo (glejte poglavje 4. 5).
Kaletra does not inhibit CYP2D6, CYP2C9, CYP2C19, CYP2E1, CYP2B6 or CYP1A2 at clinically relevant concentrations (see section 4.3).
Zdravilo Kaletra v klinično pomembnih koncentracijah ne zavira CYP2D6, CYP2C9, CYP2C19, CYP2E1, CYP2B6 ali CYP1A2 (glejte poglavje 4. 3).
Kaletra has been shown in vivo to induce its own metabolism and to increase the biotransformation of some medicinal products metabolised by cytochrome P450 enzymes and by glucuronidation.
In vivo je dokazano, da zdravilo Kaletra inducira svojo lastno presnovo in zvečuje biotransformacijo nekaterih zdravil, ki se presnavljajo z encimi citokroma P450 in z glukuronidacijo.
Medicinal products that are contraindicated specifically due to the expected magnitude of interaction and potential for serious adverse events are listed in section 4.3.
Zdravila, ki so kontraindicirana prav zaradi pričakovane izrazitosti interakcije in potenciala za resne neželene učinke, so navedena v poglavju 4. 3.
Antiretroviral agents
6 Protiretrovirusna zdravila
Nucleoside/ Nucleotide reverse transcriptase inhibitors (NRTIs):
Nukleozidni/ nukleotidni zaviralci reverzne transkriptaze (NRTI – Nucleoside/ nucleotide reverse transcriptase inhibitors):
Stavudine and Lamivudine: no change in the pharmacokinetics of lopinavir was observed when Kaletra was given alone or in combination with stavudine and lamivudine in clinical studies.
Stavudin in lamivudin: med uporabo zdravila Kaletra samega ali v kombinaciji s stavudinom in lamivudinom v kliničnih raziskavah niso opazili sprememb v farmakokinetiki lopinavirja.
Didanosine: it is recommended that didanosine be administered on an empty stomach; therefore, didanosine is to be given one hour before or two hours after Kaletra (given with food).
Didanozin: didanozin je priporočljivo jemati na prazen želodec, zato ga je treba uporabiti eno uro pred zdravilom Kaletra ali dve uri po zdravilu Kaletra (zdravilo Kaletra je treba dati s hrano).
The gastroresistant formulation of didanosine should be administered at least two hours after a meal.
Gastrorezistenten pripravek didanozina je treba uporabiti najmanj dve uri po jedi.
6 Zidovudine and Abacavir:
Zidovudin in abakavir:
Kaletra induces glucuronidation, therefore Kaletra has the potential to reduce zidovudine and abacavir plasma concentrations.
Zdravilo Kaletra inducira glukuronidacijo, zato lahko zmanjša plazemsko koncentracijo zidovudina in abakavirja.
The clinical significance of this potential interaction is unknown.
Klinični pomen te možne interakcije ni znan.
Tenofovir: when tenofovir disoproxil fumarate was co-administered with Kaletra, tenofovir concentrations were increased by approximately 30% with no changes noted in lopinavir or ritonavir concentrations.
Pri sočasni uporabi tenofovirijevega dizoproksilfumarata z zdravilom Kaletra se je koncentracija tenofovirja zvišala za približno 30%, koncentraciji lopinavirja in ritonavirja pa se nista spremenili.
Higher tenofovir concentrations could potentiate tenofovir associated adverse events, including renal disorders.
Višje koncentracije tenofovirja bi lahko povečale z njim povezane neželene učinke, vključno z ledvičnimi motnjami.
Non-nucleoside reverse transcriptase inhibitors (NNRTIs):
Nenukleozidni zaviralci reverzne transkriptaze (NNRTI - Non- nucleoside reverse transcriptase inhibitors):
Nevirapine: no change in the pharmacokinetics of lopinavir was apparent in healthy volunteers during nevirapine and Kaletra co-administration.
Nevirapin: pri zdravih prostovoljcih se farmakokinetika lopinavirja med hkratno uporabo nevirapina in zdravila Kaletra ni spremenila.
Results from a study in HIV-positive paediatric patients revealed a decrease in lopinavir concentrations during nevirapine co-administration.
Rezultati študije pri HIV- pozitivnih pediatričnih bolnikih so med hkratno uporabo nevirapina pokazali zmanjšanje koncentracije lopinavirja.
The effect of nevirapine in HIV-positive adults is expected to be similar to that in paediatric patients and lopinavir concentrations may be decreased.
Pri HIV- pozitivnih odraslih je mogoče pričakovati podoben učinek nevirapina kot pri pediatričnih bolnikih in koncentracija lopinavirja se lahko zmanjša.
The clinical significance of the pharmacokinetic interaction is unknown.
Klinični pomen te farmakokinetične interakcije ni znan.
No formal recommendation could be drawn on dosage adjustment when Kaletra is used in combination with nevirapine.
Formalnih priporočil za prilagoditev odmerjanja med uporabo zdravila Kaletra v kombinaciji z nevirapinom ni mogoče dati.
However, based on clinical experience, Kaletra dose increase to 533/ 133 mg (4 capsules) twice daily may be considered when co-administered with nevirapine, particularly for patients in whom reduced lopinavir susceptibility is likely.
A na podlagi kliničnih izkušenj pride v primeru sočasne uporabe z nevirapinom v poštev zvečanje odmerka zdravila Kaletra na 533/ 133 mg (4 kapsule) dvakrat na dan, zlasti pri bolnikih, ki so verjetno manj občutljivi za lopinavir.
Efavirenz: when used in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in multiple protease inhibitor-experienced patients, increasing the dose of Kaletra 33.3% from 400/ 100 mg (3 capsules) twice daily to 533/ 133 mg (4 capsules) twice daily yielded similar lopinavir plasma concentrations as compared to historical data of Kaletra 400/ 100 mg (3 capsules) twice daily.
Efavirenz: ko so zdravilo Kaletra uporabili v kombinaciji z efavirenzem in dvema nukleozidnima zaviralcema reverzne transkriptaze pri bolnikih, izkušenih z več zaviralci proteaz, je zvečanje odmerka zdravila Kaletra za 33, 3% – od 400/ 100 mg (3 kapsule) dvakrat na dan na 533/ 133 mg (4 kapsule) dvakrat na dan – povzročilo podobno plazemsko koncentracijo lopinavirja kot po preteklih podatkih zdravilo Kaletra 400/ 100 mg (3 kapsule) dvakrat na dan.
Dosage increase of Kaletra from 400/ 100 mg (3 capsules) twice daily to 533/ 133 mg (4 capsules) twice daily should be considered when co-administered with efavirenz.
V primeru sočasne uporabe z efavirenzem je treba razmisliti o zvečanju odmerka zdravila Kaletra s 400/ 100 mg (3 kapsule) dvakrat na dan na 533/ 133 mg (4 kapsule) dvakrat na dan.
Caution is warranted since this dosage adjustment might be insufficient in some patients.
Potrebna je previdnost, kajti ta prilagoditev odmerka ne zadošča za vse bolnike.
Co-administration with other HIV protease inhibitors (PIs):
Sočasna uporaba z drugimi zaviralci proteaz (ZP) HIV:
Kaletra (400/ 100 mg twice daily) has been studied in combination with reduced doses of amprenavir, indinavir, nelfinavir and saquinavir in steady-state controlled healthy volunteer studies relative to clinical doses of each HIV protease inhibitor in the absence of ritonavir.
Zdravilo Kaletra (400/ 100 mg dvakrat na dan) so raziskali v kombinaciji z zmanjšanimi odmerki amprenavirja, indinavirja, nelfinavirja in sakvinavirja v ravnotežnem stanju v študijah zdravih prostovoljcev v primerjavi s kliničnimi odmerki vsakega teh zaviralcev proteaz HIV brez ritonavirja.
Comparisons to published pharmacokinetic data with ritonavir-enhanced amprenavir and saquinavir regimens are also described.
Opisane so tudi primerjave z objavljenimi farmakokinetičnimi podatki za sheme amprenavirja in sakvinavirja z ritonavirjem kot stopnjevalcem.
Additionally, the effect of additional ritonavir on the pharmacokinetics of lopinavir are discussed.
Poleg tega razpravljajo o učinku dodatnega ritonavirja na farmakokinetiko lopinavirja.
Note that the historical comparisons to ritonavir-enhanced protease inhibitor regimens should be interpreted with caution (see details of combinations below).
Opozoriti je treba, da je potrebno retrospektivne primerjave s shemami zaviralcev proteaz, stopnjevanimi z ritonavirjem, tolmačiti previdno (glejte podrobnosti o kombinacijah v nadaljevanju).
Appropriate doses of HIV-protease inhibitors in combination with Kaletra with respect to safety and efficacy have not been established.
Glede varnosti in učinkovitosti ustrezni odmerki zaviralcev proteaze HIV v kombinaciji z zdravilom Kaletra niso ugotovljeni.
Therefore, the concomitant administration of Kaletra with PIs requires close monitoring.
Zato zahteva sočasna uporaba zdravila Kaletra in ZP skrbno nadziranje.
Amprenavir: the concomitant use of Kaletra with amprenavir 750 mg twice daily, resulted in an increase in amprenavir AUC by 70% and of Cmin by 4.6-fold, relative to amprenavir 1200 mg twice daily alone.
7 Amprenavir: sočasna uporaba zdravila Kaletra s 750 mg amprenavirja dvakrat na dan je v primerjavi s 1200 mg samega amprenavirja dvakrat na dan zvečala AUC amprenavirja za 70% in Cmin za 4, 6- krat.
On the other hand, the AUC of lopinavir decreases by 38%.
Po drugi strani se AUC lopinavirja zmanjša za 38%.
A dose increase of Kaletra may be necessary but may further affect concentrations of amprenavir.
Potrebno utegne biti zvečanje odmerka zdravila Kaletra, kar pa lahko še dodatno vpliva na koncentracijo amprenavirja.
Combined with Kaletra, amprenavir concentrations were lower (approximately 30%) relative to boosted amprenavir (amprenavir 600 mg/ ritonavir 100 mg) twice daily alone.
V kombinaciji z zdravilom Kaletra je bila koncentracija amprenavirja nižja (približno 30%) v primerjavi s samim stopnjevanim amprenavirjem (amprenavir 600 mg/ ritonavir 100 mg) dvakrat na dan.
Fosamprenavir: co-administration of standard doses of lopinavir/ ritonavir with fosamprenavir results in a significant reduction in amprenavir concentrations.
Sočasna uporaba standardnih odmerkov lopinavirja/ ritonavirja s fosamprenavirjem bistveno zmanjša koncentracijo amprenavirja.
Co-administration of increased doses of fosamprenavir 1400 mg twice daily with lopinavir/ ritonavir 533/ 133 mg twice daily to protease inhibitor-experienced patients resulted in a higher incidence of gastrointestinal adverse events and elevations in triglycerides with the combination regimen without increases in virological efficacy,
Pri bolnikih, ki so že dobivali zaviralce proteaz, je sočasna uporaba večjih odmerkov fosamprenavirja 1400 mg dvakrat na dan z lopinavirjem/ ritonavirjem 533/ 133 mg dvakrat na dan povečala incidenco neželenih učinkov na prebavila in zvišanja trigliceridov s kombinirano shemo.
7 when compared with standard doses of fosamprenavir/ ritonavir.
Ob tem se virološka učinkovitost v primerjavi s standardnimi odmerki fosamprenavirja/ ritonavirja ni povečala.
Therefore, concomitant administration of these medicinal products is not recommended.
Sočasna uporaba teh zdravil zato ni priporočljiva.
Indinavir: indinavir 600 mg twice daily in combination with Kaletra produces similar indinavir AUC, higher Cmin (by 3.5-fold) and lower Cmax relative to indinavir 800 mg three times daily alone.
Indinavir: indinavir v odmerku 600 mg dvakrat na dan v kombinaciji z zdravilom Kaletra doseže podobno AUC, večjo Cmin (za 3, 5- krat) in manjšo Cmax kot sam indinavir v odmerku 800 mg trikrat na dan.
Furthermore, concentrations of lopinavir do not appear to be affected when both medicinal products, Kaletra and indinivir, are combined, based on historical comparison with Kaletra alone.
Poleg tega na podlagi retrospektivne primerjave s samim zdravilom Kaletra ne kaže, da bi se koncentracija lopinavirja spremenila, če sta zdravilo Kaletra in indinavir uporabljena v kombinaciji.
Nelfinavir: administration of nelfinavir 1000 mg twice daily in combination with Kaletra produces a similar nelfinavir Cmax and AUC and higher Cmin relative to nelfinavir 1250 mg twice daily alone.
Nelfinavir: uporaba 1000 mg nelfinavirja dvakrat na dan v kombinaciji z zdravilom Kaletra povzroči podobni Cmax in AUC nelfinavirja ter večjo Cmin kakor sam nelfinavir v odmerku 1250 mg dvakrat na dan.
Additionally, concentrations of the active M8 metabolite of nelfinavir were increased.
Poleg tega se zveča koncentracija M8, aktivnega presnovka nelfinavirja.
On the other hand, lopinavir AUC was decreased by 27% during nelfinavir co-administration with Kaletra.
Po drugi strani pa se je med sočasno uporabo nelfinavirja in zdravila Kaletra AUC lopinavirja zmanjšala za 27%.
A dose increase of Kaletra may be necessary but may further affect concentrations of nelfinavir and its active metabolite.
Potrebno utegne biti zvečanje odmerka zdravila Kaletra, kar pa lahko dodatno vpliva na koncentracijo nelfinavirja in njegovega aktivnega presnovka.
Higher doses of Kaletra have not been studied.
Večji odmerki zdravila Kaletra niso raziskani.
Saquinavir: saquinavir 800 mg twice daily co-administered with Kaletra produces an increase of saquinavir AUC by 9.6-fold relative to saquinavir 1200 mg three times daily given alone.
Sakvinavir: sakvinavir 800 mg dvakrat na dan doseže ob sočasni uporabi z zdravilom Kaletra 9, 6- krat večjo AUC kot sakvinavir sam v odmerku 1200 mg trikrat na dan.
Saquinavir 800 mg twice daily co-administered with Kaletra resulted in an increase of saquinavir AUC by approximately 30% relative to saquinavir/ ritonavir 1000/ 100 mg twice daily, and produces similar exposure to those reported after saquinavir/ ritonavir 400/ 400 mg twice daily.
Uporaba sakvinavirja v odmerku 800 mg dvakrat na dan sočasno z zdravilom Kaletra je povzročila približno 30% večjo AUC sakvinavirja kot kombinacija sakvinavir/ ritonavir 1000/ 100 mg dvakrat na dan ter podobno izpostavljenost, kot je opisana po kombinaciji sakvinavir/ ritonavir 400/ 400 mg dvakrat na dan.
When saquinavir 1200 mg twice daily was combined with Kaletra, no further increase of concentrations was noted.
Če so 1200 mg sakvinavirja dvakrat na dan kombinirali z zdravilom Kaletra, niso opazili dodatnega zvečanja koncentracije.
Furthermore, concentrations of lopinavir do not appear to be affected when both medicinal products, Kaletra and saquinavir, are combined, based on historical comparison with Kaletra alone.
Na podlagi retrospektivne primerjave s samim zdravilom Kaletra kaže, da kombinirana uporaba zdravila Kaletra in sakvinavirja ne vpliva na koncentracijo lopinavirja.
Kaletra co-administered with an additional 100 mg ritonavir twice daily resulted in an increase of lopinavir AUC and Cmin of 33% and 64%, respectively, as compared to Kaletra alone.
Zdravilo Kaletra, uporabljeno hkrati z dodatnimi 100 mg ritonavirja dvakrat na dan, je zvečala AUC lopinavirja za 33% in Cmin za 64% v primerjavi s samim zdravilom Kaletra.
Other medicinal products:
Druga zdravila:
Acid reducing agents (omeprazole, ranitidine): in a study performed in healthy volunteers, no clinically relevant interaction has been observed when Kaletra tablets 400/ 100 mg twice daily was co-administered with omeprazole or with ranitidine.
Med uporabo tablet Kaletra 400/ 100 mg dvakrat na dan hkrati z omeprazolom ali ranitidinom v študiji pri zdravih prostovoljcih niso ugotovili klinično pomembnih interakcij.
Kaletra can be co-administered with acid reducing agents with no dose adjustment.
Zdravilo Kaletra je mogoče uporabljati sočasno z zdravili, ki zmanjšajo izločanje kisline, ne da bi bilo treba prilagoditi odmerek.
Antiarrhythmics (bepridil, systemic lidocaine and quinidine): concentrations may be increased when co-administered with Kaletra.
Antiaritmiki (bepridil, sistemski lidokain in kinidin): med sočasno uporabo z zdravilom Kaletra se njihova koncentracija lahko zveča.
Caution is warranted and therapeutic concentration monitoring is recommended when available.
Priporočljiva je previdnost in, če je mogoče, merjenje terapevtskih koncentracij.
Anticancer agents (eg vincristine, vinblastine): these agents may have their serum concentrations increased when co-administered with lopinavir/ ritonavir resulting in the potential for increased adverse events usually associated with these anticancer agents.
Koncentracija teh zdravil v serumu se lahko med sočasno uporabo s kombinacijo lopinavir/ ritonavir poveča, zato se lahko povečajo neželeni učinki, ki so ponavadi povezani s temi zdravili proti raku.
Anticoagulants: warfarin concentrations may be affected when co-administered with Kaletra.
Antikoagulanti: če je varfarin uporabljen hkrati z zdravilom Kaletra, to lahko vpliva na njegovo koncentracijo.